Introduce yourself
I'm Orris, a knowledgeable AI assistant here to help you across a wide range of topics.
Here's what I can do for you:
- Medical & Clinical — drug mechanisms, diagnoses, anatomy, physiology, treatment guidelines, and more, backed by authoritative medical textbooks and peer-reviewed literature
- Research — searching PubMed, synthesizing evidence, finding recent studies and clinical trials
- Document Creation — Word docs, PowerPoint presentations, Excel spreadsheets, and PDFs
- Web Research — finding current information, news, and up-to-date facts
- Code & Data — writing scripts, analyzing data, running computations in a live sandbox environment
- General Knowledge — science, history, technology, finance, and more
What can I help you with today?
Are you free or paid
That depends on the platform you're accessing me through — I'm Orris, and my availability (free or paid) is determined by whoever deployed me, not by me directly.
If you're unsure, check the platform or app you're using to chat with me for pricing or subscription details.
Is there something I can help you with?
Are you available as app
I don't have information about whether Orris is available as a standalone app. That's a question best directed to the team or organization that deployed me.
What I can tell you is that right now, you're already talking to me — so whatever interface you're using is working! Is there anything I can help you with?
Classification of beta blocker
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive information from Goodman & Gilman's and Barash's Clinical Anesthesia to provide a full classification. Here is the structured answer:
Classification of Beta-Blockers (β-Adrenergic Receptor Antagonists)
Beta-blockers are classified into three generations based on receptor selectivity and additional cardiovascular properties.
Generation 1 — Non-Selective β-Blockers (Classical)
Block both β₁ and β₂ adrenoceptors equally.
| Drug | ISA | MSA | Lipid Solubility |
|---|---|---|---|
| Propranolol (prototype) | 0 | ++ | High |
| Nadolol | 0 | 0 | Low |
| Timolol | 0 | 0 | Low–Moderate |
| Pindolol | +++ | + | Low |
| Penbutolol | + | 0 | High |
ISA = Intrinsic Sympathomimetic Activity (partial agonist); MSA = Membrane Stabilizing Activity
Key points:
- Propranolol is the prototype — first β-blocker in clinical use
- Non-selective blockade of β₂ → risk of bronchoconstriction (avoid in asthma), peripheral vasoconstriction, and masking hypoglycemia
- Pindolol has high ISA → avoids resting bradycardia
Generation 2 — Cardioselective (β₁-Selective) Blockers
Preferentially block β₁ receptors (cardiac); β₂ selectivity is dose-dependent — lost at high doses.
| Drug | ISA | MSA | Half-life |
|---|---|---|---|
| Atenolol | 0 | 0 | 6–7 hrs |
| Metoprolol | 0 | + | 3–7 hrs |
| Esmolol | 0 | 0 | ~9 min (ultra-short) |
| Bisoprolol | 0 | 0 | 9–12 hrs |
| Acebutolol | + | + | 3–4 hrs |
Key points:
- Preferred over non-selective agents in COPD, diabetes, PVD
- Esmolol is ultra-short acting (IV only) — useful intraoperatively
- Still avoid in asthma if possible; selectivity is relative
Generation 3 — Beta-Blockers With Additional Cardiovascular Effects (Vasodilatory)
Retain β-blockade but also cause vasodilation via various mechanisms:
| Drug | Additional Mechanism | β-Selectivity |
|---|---|---|
| Labetalol | α₁ blockade | Non-selective (β + α₁) |
| Carvedilol | α₁ blockade + antioxidant + Ca²⁺ channel blockade | Non-selective |
| Nebivolol | NO-mediated vasodilation (endothelium) | β₁-selective |
| Celiprolol | NO production + β₂ agonism | β₁-selective |
| Bucindolol | ISA (partial β₁ agonist) | Non-selective |
Key points:
- Labetalol: β blockade is 5–10× more potent than its α₁ blockade; available IV for hypertensive emergencies
- Carvedilol: drug of choice in HFrEF (along with metoprolol succinate, bisoprolol)
- Nebivolol: most β₁-selective; vasodilation via endothelial NO release
Additional Classification Axes
By Lipid Solubility (CNS Penetration)
| Lipophilic (CNS effects) | Hydrophilic (renal elimination) |
|---|---|
| Propranolol, Metoprolol, Carvedilol | Atenolol, Nadolol |
By Intrinsic Sympathomimetic Activity (ISA)
- With ISA: Pindolol, Penbutolol, Acebutolol, Celiprolol
- Without ISA: Propranolol, Atenolol, Metoprolol, Bisoprolol, Carvedilol
- ISA agents cause less resting bradycardia but are avoided in angina and post-MI patients
By Route / Duration
- Ultra-short IV: Esmolol (~9 min t½)
- Short-acting: Propranolol, Metoprolol tartrate
- Long-acting: Atenolol, Bisoprolol, Nadolol, Metoprolol succinate (XL)
Summary Table
| Generation | Receptor | Example Drugs | Key Feature |
|---|---|---|---|
| 1st | β₁ + β₂ (non-selective) | Propranolol, Nadolol, Timolol, Pindolol | Prototype class |
| 2nd | β₁ (cardioselective) | Atenolol, Metoprolol, Esmolol, Bisoprolol | Preferred clinically |
| 3rd | β₁/β₁+β₂ + vasodilation | Labetalol, Carvedilol, Nebivolol | Extra vascular effects |
Sources: Goodman & Gilman's The Pharmacological Basis of Therapeutics; Barash, Cullen & Stoelting's Clinical Anesthesia, 9e; Lippincott Illustrated Reviews: Pharmacology
This is a shared conversation. Sign in to Orris to start your own chat.